BUSINESS
Healios, Hiroshima Univ. to Collaborate on Cancer Immunotherapy Using Gene-Edited NK Cells
Tokyo based biotech Healios and Hiroshima University said on December 21 that they have entered a joint research agreement regarding an immunotherapy for hepatocellular carcinoma that uses genetically edited natural killer (NK) cells. The partners will evaluate it in animal…
To read the full story
BUSINESS
- Astellas Confirms Applying to US MFN Medicaid Pricing Model
July 7, 2026
- Tanabe to Sell Manufacturing Unit to Towa, Transfer 17 Products
July 6, 2026
- Espha Launches Generic Forxiga; Nipro AG Due in September
July 6, 2026
- GNI Targets Above-Industry Growth in Japan after Ayumi Buyout
July 3, 2026
- Sawai Prevails in ALS Drug Contract Appeal against Neugen
July 3, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…





